Nichi-Iko Pharmaceutical to Buy Sagent in $736 Million Cash DealBy
Bid represents 40 percent premium of over last closing price
Establishes toehold in U.S. market amid expansion plans
Nichi-Iko Pharmaceutical Co. agreed to buy Sagent Pharmaceuticals Inc. for $736 million in cash, allowing the Japanese company to build its presence in the U.S. market as it looks to become one of the world’s top manufacturers of generic medicines.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.